BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 19190917)

  • 1. Whole-body MRI at 1.5 T and 3 T compared with FDG-PET-CT for the detection of tumour recurrence in patients with colorectal cancer.
    Schmidt GP; Baur-Melnyk A; Haug A; Utzschneider S; Becker CR; Tiling R; Reiser MF; Hermann KA
    Eur Radiol; 2009 Jun; 19(6):1366-78. PubMed ID: 19190917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive imaging of tumor recurrence in breast cancer patients using whole-body MRI at 1.5 and 3 T compared to FDG-PET-CT.
    Schmidt GP; Baur-Melnyk A; Haug A; Heinemann V; Bauerfeind I; Reiser MF; Schoenberg SO
    Eur J Radiol; 2008 Jan; 65(1):47-58. PubMed ID: 18082989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-resolution whole-body magnetic resonance image tumor staging with the use of parallel imaging versus dual-modality positron emission tomography-computed tomography: experience on a 32-channel system.
    Schmidt GP; Baur-Melnyk A; Herzog P; Schmid R; Tiling R; Schmidt M; Reiser MF; Schoenberg SO
    Invest Radiol; 2005 Dec; 40(12):743-53. PubMed ID: 16304476
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive imaging of residual/ recurrent nasopharyngeal carcinoma using whole-body MRI at 3 T compared with FDG-PET-CT.
    Ng SH; Chan SC; Yen TC; Liao CT; Chang JT; Ko SF; Wang HM; Lin CY; Chang KP; Lin YC
    Eur Radiol; 2010 Sep; 20(9):2229-40. PubMed ID: 20393714
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Staging of colon cancer: whole-body MRI vs. whole-body PET-CT--initial clinical experience.
    Squillaci E; Manenti G; Mancino S; Cicciò C; Calabria F; Danieli R; Schillaci O; Simonetti G
    Abdom Imaging; 2008; 33(6):676-88. PubMed ID: 18373114
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Whole-body MRI with diffusion-weighted sequence for staging of patients with suspected ovarian cancer: a clinical feasibility study in comparison to CT and FDG-PET/CT.
    Michielsen K; Vergote I; Op de Beeck K; Amant F; Leunen K; Moerman P; Deroose C; Souverijns G; Dymarkowski S; De Keyzer F; Vandecaveye V
    Eur Radiol; 2014 Apr; 24(4):889-901. PubMed ID: 24322510
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison of high resolution whole-body MRI using parallel imaging and PET-CT. First experiences with a 32-channel MRI system].
    Schmidt GP; Baur-Melnyk A; Tiling R; Hahn K; Reiser MF; Schoenberg SO
    Radiologe; 2004 Sep; 44(9):889-98. PubMed ID: 15349732
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Screening for bone metastases: whole-body MRI using a 32-channel system versus dual-modality PET-CT.
    Schmidt GP; Schoenberg SO; Schmid R; Stahl R; Tiling R; Becker CR; Reiser MF; Baur-Melnyk A
    Eur Radiol; 2007 Apr; 17(4):939-49. PubMed ID: 16951929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the utility of whole-body MRI with and without contrast-enhanced Quick 3D and double RF fat suppression techniques, conventional whole-body MRI, PET/CT and conventional examination for assessment of recurrence in NSCLC patients.
    Ohno Y; Nishio M; Koyama H; Yoshikawa T; Matsumoto S; Takenaka D; Seki S; Tsubakimoto M; Sugimura K
    Eur J Radiol; 2013 Nov; 82(11):2018-27. PubMed ID: 24012452
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Whole-body MRI, FDG-PET/CT, and bone marrow biopsy, for the assessment of bone marrow involvement in patients with newly diagnosed lymphoma.
    Albano D; Patti C; Lagalla R; Midiri M; Galia M
    J Magn Reson Imaging; 2017 Apr; 45(4):1082-1089. PubMed ID: 27603267
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Whole-body-MR imaging including DWIBS in the work-up of patients with head and neck squamous cell carcinoma: a feasibility study.
    Noij DP; Boerhout EJ; Pieters-van den Bos IC; Comans EF; Oprea-Lager D; Reinhard R; Hoekstra OS; de Bree R; de Graaf P; Castelijns JA
    Eur J Radiol; 2014 Jul; 83(7):1144-1151. PubMed ID: 24768188
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 18F-FDG PET/CT and whole-body MRI diagnostic performance in M staging for non-small cell lung cancer: a systematic review and meta-analysis.
    Machado Medeiros T; Altmayer S; Watte G; Zanon M; Basso Dias A; Henz Concatto N; Hoefel Paes J; Mattiello R; de Souza Santos F; Mohammed TL; Verma N; Hochhegger B
    Eur Radiol; 2020 Jul; 30(7):3641-3649. PubMed ID: 32125513
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-body diffusion-weighted imaging vs. FDG-PET for the detection of non-small-cell lung cancer. How do they measure up?
    Chen W; Jian W; Li HT; Li C; Zhang YK; Xie B; Zhou DQ; Dai YM; Lin Y; Lu M; Huang XQ; Xu CX; Chen L
    Magn Reson Imaging; 2010 Jun; 28(5):613-20. PubMed ID: 20418042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of ¹⁸F-FDG PET/MRI, ¹⁸F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer.
    Sawicki LM; Grueneisen J; Schaarschmidt BM; Buchbender C; Nagarajah J; Umutlu L; Antoch G; Kinner S
    Eur J Radiol; 2016 Feb; 85(2):459-65. PubMed ID: 26781152
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDG-PET-CT and whole-body MRI for triage in patients planned for radioembolisation therapy.
    Schmidt GP; Paprottka P; Jakobs TF; Hoffmann RT; Baur-Melnyk A; Haug A; Notohamiprodjo M; Baur-Melnyk A; Nikolaou K; Reiser MF; Rist C
    Eur J Radiol; 2012 Mar; 81(3):e269-76. PubMed ID: 21398060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of whole-body MRI including diffusion-weighted sequences in the initial staging of breast cancer patients at high risk of metastases in comparison with PET-CT: a prospective cohort study.
    Hottat NA; Badr DA; Ben Ghanem M; Besse-Hammer T; Lecomte SM; Vansteelandt C; Lecomte SL; Khaled C; De Grove V; Salem Wehbe G; Cannie MM; Jani JC
    Eur Radiol; 2024 Jan; 34(1):165-178. PubMed ID: 37555959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Whole-body staging of malignant melanoma: advantages, limitations and current importance of PET-CT, whole-body MRI and PET-MRI].
    Pfannenberg C; Schwenzer N
    Radiologe; 2015 Feb; 55(2):120-6. PubMed ID: 25589421
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of combined FDG-PET/CT and MRI on the detection of local recurrence and nodal metastases in thyroid cancer.
    Hempel JM; Kloeckner R; Krick S; Pinto Dos Santos D; Schadmand-Fischer S; Boeßert P; Bisdas S; Weber MM; Fottner C; Musholt TJ; Schreckenberger M; Miederer M
    Cancer Imaging; 2016 Nov; 16(1):37. PubMed ID: 27809936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical impact of fluorodeoxyglucose-positron emission tomography scan/computed tomography in comparison with computed tomography on the detection of colorectal cancer recurrence.
    Deleau C; Buecher B; Rousseau C; Kraeber-Bodéré F; Flamant M; des Varannes SB; Frampas E; Galmiche JP; Matysiak-Budnik T
    Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):275-81. PubMed ID: 21304319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pretreatment evaluation of distant-site status in patients with nasopharyngeal carcinoma: accuracy of whole-body MRI at 3-Tesla and FDG-PET-CT.
    Ng SH; Chan SC; Yen TC; Chang JT; Liao CT; Ko SF; Wang HM; Wai YY; Wang JJ; Chen MC
    Eur Radiol; 2009 Dec; 19(12):2965-76. PubMed ID: 19588148
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.